Transient receptor potential vanilloid subtype 1 (TRPV1) is a non-selective cation channel activated by capsaicin. TRPV1 is expressed not only on human sensory neurons but also on human epidermal and hair follicle keratinocytes. Therefore, TRPV1 could have the potential to be a therapeutic target for skin disorders. To search for novel TRPV1 agonists, we screened 31 essential oils by using human TRPV1-expressing HEK293 cells. TRPV1 was activated by 4 essential oils: rose, thyme geraniol, palmarosa, and tolu balsam. The dose-response curves for TRPV1 activation by the essential oils revealed a rank order potency [the half-maximal effective concentration (EC 50 )] of roseϾpalmarosaϾthyme geraniolϾtolu balsam, and rank order efficiency (% activity in response to 1 mM capsaicin) of tolu balsamϾroseϾpalmarosaϾthyme geraniol. Moreover, the dose-response curves for TRPV1 activation by citronellol (main constituent of rose oil) and geraniol (main constituent of thyme geraniol and palmarosa oils) were consistent with the potency and efficiency of each essential oil. In contrast, benzyl cinnamate and benzyl benzoate (main constituent of tolu balsam oil) and geranyl acetate (main constituent of thyme geraniol oil) did not show TRPV1 activity. In this first-of-its-kind study, we successfully investigated the role of some essential oils in promoting human TRPV1 activation, and also identified two monoterpenes, citronellol and geraniol, as new human TRPV1 agonists.
Transient receptor potential vanilloid subtype 1 (TRPV1) is a nonselective cation channel activated by capsaicin (a pungent ingredient of red pepper), 1) heat (Ͼ43°C), acidic pH, 2) lipid, 3, 4) and various natural products. [5] [6] [7] [8] [9] Although TRPV1 is known to be involved in peripheral nociception, 10, 11) it is also widely expressed on human epidermal [12] [13] [14] and hair follicle keratinocytes. 15) In addition, TRPV1 signaling plays physiologically important roles in normal functioning of the human skin. Bodó et al. have recently provided the first evidence towards this with their discovery that TRPV1 activation promotes hair follicle regression, hair matrix keratinocyte apoptosis, inhibits hair matrix keratinocyte proliferation, and retards hair shaft elongation. 16) TRPV1 agonists have been recently proposed as therapeutic targets not only in acute neuropathic pain but also in skin disorders. 17) Many plant-derived essential oils have been used traditionally to treat various skin disorders. 18) The medicinal use of essential oils that began in ancient Egypt has continued ever since and aromatherapy 19) has recently become popular worldwide. In addition, essential oils may provide a therapeutic alternative to western medicine. 20) However, the lack of a scientific basis evaluating the effectiveness of essential oils is an impediment to its increased use.
Essential oils are naturally occurring complex, multicomponent systems composed mainly of monoterpenes in addition to some non-terpene components. 21) Because TRPV1 is known to be activated by certain monoterpene, including camphor, 22) we speculated that the various pharmacological actions of essential oils may exercise through TRPV1.
The aim of this study was to search for novel compounds that activate human TRPV1, for which we screened 31 commercially available essential oils noted for their remedial properties against skin disorders.
18) This was achieved by measuring the intracellular Ca 2ϩ concentration ([Ca   2ϩ ] i ) in human TRPV1-expressing HEK293 cells.
MATERIALS AND METHODS

Materials
Capsaicin, capsazepine (CPZ), citronellol, geraniol, geranyl acetate, benzyl benzoate and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich Co. (St. Louis, MO, U.S.A.). Benzyl cinnamate was purchased from Tokyo Kasei Kogyo Co., Ltd. (Tokyo, Japan). Essential oils were purchased from PLANAROM International (Ghislenghien, Belgium).
Cloning of Human TRPV1 Oligo(dT) primed cDNA was synthesized from 5 mg of the total RNA isolated from human dorsal root ganglion (Clontech, Mountain View, CA , U.S.A.) using a SuperScript TM III first-strand synthesis system for reverse transcription-polymerase chain reaction (RT-PCR) (Invitrogen, Carlsbad, CA, U.S.A.) according to the manufacturer's instructions. An aliquot of the first cDNA (2 ml) was then subjected to PCR amplification with the use of Pfx DNA polymerase (Invitrogen) using the following primers 5Ј-CACCATGAAGAAATGGAGCAGC-3Ј (N-terminal forward primer with CACC sequence) and 5Ј-CTT-CTCCCCGGAAGCGGCAG-3Ј (C-terminal reverse primer without the stop codon). The PCR products were then separated on a 0.7% agarose gel, and the bands were excised, purified using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA, U.S.A. Line HEK293 cells containing FLP recombination site (Invitrogen) were cotransfected with hTRPV1-pcDNA5/FRT and pOG44 vectors (Invitrogen) using lipofectamine LTX (Invitrogen). Stable clones expressing TRPV1 were then selected using hygromycin B antibiotic selection and colonies were expanded to produce a large stock of TRPV1-expressing cells. TRPV1 protein expression was confirmed by Western blotting.
Western Blotting Cells were lysed in 200 ml of lysis buffer [20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and protease inhibitor cocktail (Sigma-Aldrich Co.), pH 7.5]. After 30 min of solubilization at 4°C under agitation, lysates were centrifuged (16000 g, 10 min, 4°C). Protein extracts were diluted in 2ϫ Laemmli buffer, resolved by SDS-polyacrylamide gel electrophoresis, and transferred to polyvinyliden difluoride membranes. Blocking was performed using 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween 20 followed by incubation with anti-V5-HRP antibody (diluted at 1 : 5000: Invitrogen) in the blocking buffer at 4°C overnight. After a 15-min wash with Trisbuffered saline containing 0.1% Tween 20, membranes were incubated for 1 h with anti-rabbit horseradish peroxidaseconjugated secondary antibody (diluted at 1 : 1000) from GE Healthcare (Chalfont St. Giles, Buckinghamshire, U.K.). Chemifluorescence (enhanced chemiluminescence-plus; GE Healthcare, Piscataway, NJ, U.S.A.) was detected using the Typhoon 9400 Variable Mode Imager and ImageQuant analysis GE Healthcare.
Intracellular Calcium Measurement on the FlexStation Cells were plated at 80-90% confluence on 96-well, poly-Dlysine black-walled, clear-bottomed plates (Griner bio-one, Frickenhausen, Germany) 24 h prior to initiating the experiments. The cells were incubated for 1 h at 37°C in Hank's balanced salt solution (HBSS) buffer (HBSS plus 20 mM HEPES buffer, pH 7.4) containing FLIPR ® calcium 4 assay reagent (Molecular Devices, Sunnyvale, CA, U.S.A.) followed immediately by fluorescence measurement. Fluorescence was measured using FlexStation (excitation at 485 nm and emission at 525 nm, using a 515 nm cut off) and SoftMax Pro 4.7.1 software (Molecular Devices). Experiments were performed at room temperature (30°C). In some experiments, CPZ (10 mM) was added at least 1 min prior to the addition of the test compounds and essential oils. The test compound and essential oils were prepared in DMSO and add to the HBSS buffer (final DMSO conc. 0.2%). EC 50 values were determined using Prism 4 software (GraphPad Software, La Jolla, CA, U.S.A.).
RESULTS AND DISCUSSION
Firstly, expression of human TRPV1 in cloned TRPV1-expressing HEK293 cells were confirmed by the Western blotting (Fig. 1A) . TRPV1 positive bands were detected with apparent molecular weights of 95 kDa, and a highly glycosylated form of TRPV1 at 120 kDa, consistent with the previous report by Vos et al. 23) No bands were detected for TRPV1 from nontransfected HEK293 cells. In addition, capsaicin produced a dose-dependent increase in [Ca 2ϩ ] i levels in this cloned TRPV1-expressing HEK293 cells (Fig. 1B) , an estimated EC 50 of 0.0158 mM, similar to the values previously reported for human TRPV1 obtained using the FLIPR assay (EC 50 values of 0.0173 mM; Bianchi et al. 24) ). Next, thirty-one essential oils were examined at two concentrations (0.005, 0.02%) for TRPV1 activation by calcium imaging of TRPV1-expressing HEK293 cells (Fig. 2) . We discovered four essential oils (thyme geraniol, tolu balsam, palmarosa, and rose) that increased [Ca 2ϩ ] i levels in TRPV1- expressing HEK293 cells. The dose-response curves for TRPV1 activation by these essential oils revealed a rank order potency (EC 50 ) of rose (0.001%)Ͼpalmarosa (0.002%) Ͼthyme geraniol (0.003%)Ͼtolu balsam (0.005%) oils, and rank order efficiency (% activity in response to 1 mM capsaicin) of tolu balsam (61Ϯ4.5%)Ͼrose (45Ϯ0.3%)Ͼpal-marosa (36Ϯ1.1%)Ͼthyme geraniol (30Ϯ1.6%) oils (Fig.  3A) . The response of these essential oils were inhibited by 10 mM CPZ (Fig. 3B) and were not observed in nontransfected HEK293 cells (data not shown), proving that these essential oils are specific agonists of human TRPV1.
To determine the specific essential oil constituents that contribute to the TRPV1 activation, we analyzed all oils and compared the activities of their main constituents. These constituents are listed in Table 1 .
The dose-response curves for TRPV1 activation by citronellol (main constituent of rose oil), geraniol (main constituent of thyme geraniol and palmarosa oils) revealed a rank order potency of citronellol (43 mM)Ͼgeraniol (102 mM), and rank order efficiency of citronellol (45Ϯ4.9%)Ͼgeraniol (39Ϯ4.1%) (Fig. 4B) . The response of these constituents were inhibited by 10 mM CPZ (Fig. 4C ) and were not observed in nontransfected HEK293 cells (data not shown), proving that these essential oils are specific agonists of human TRPV1. Citronellol accounted for 39% with a concentration of 40 mM in 0.001% of rose oil as compared to geraniol which accounted for 39% and 78% with a concentration of 90 mM in 0.002% and in 0.003% of palmarosa and thyme geraniol oils, respectively. Consequently, because the potency and efficiency of citronellol and geraniol were consistent with that of essential oils, we concluded that human TRPV1 activation by rose, thyme geraniol, and palmarosa oils can be explained by the activity of each of their main constituents.
Geraniol has recently been described to activate rat TRPV1. 25) However, there are no reports evaluating the effect on geraniol on human TRPV1 activity accompanied by its EC 50 value. Therefore, this study is the first of its kind to investigate these aspects. Apart from this, our findings also suggest that benzyl cinnamate and benzyl benzoate (main constituents of tolu balsam) do not affect TRPV1 activity. This is in conflict with the results for tolu balsam. Further investigation is required to elucidate the role played by each essential oil constituent in TRPV1 activation.
The activation of TRPV1 by capsaicin and other vanilloids is believed to occur via a non-covalent binding pocket in the transmembrane domain through p-stacking interactions between the aromatic moiety of Tyr 511 and the vanilloid ring moiety of capsaicin. 26) Allicin (garlic-derived sulfide components) also activate TRPV1 27) and recently they have been shown to activate by covalent binding to intracellular cysteine residue in the N-terminal region of TRPV1. 28) Although information regarding to citronellol and geraniol remain elu- sive, it has been shown that some monoterpenes could selectivity react to cysteine residue in bovine serum albumin. 29) Therefore, the mechanism of TRPV1 activation by citronellol and geraniol may similar that of allicin.
The human TRPV1 activity brought about by these oils has not been previously reported, and has been successfully investigated by this study. Apart from determining the effect exhibited by four essential oils, this study was also the first to reveal the effect of citronellol, the main constituent of rose oil, and geraniol, the main constituent of palmarosa and thyme geraniol oils, on human TRPV1 activity. Further detailed studies are required on the structure and physiological function of these active constituents to understand their potential as therapeutic remedies for various skin disorders. 
